| Year |
Title |
Altmetric |
| 2019
|
Fibronectin on the surface of extracellular vesicles mediates fibroblast invasion
2019
|
|
| 2019
|
Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling
2019
|
|
| 2018
|
Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy
2018
|
|
| 2018
|
Proteoglycan chemical diversity drives multifunctional cell regulation and therapeutics
2018
|
|
| 2018
|
Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior
2018
|
|
| 2018
|
Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression
2018
|
|
| 2017
|
Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.
2017
|
|
| 2017
|
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
2017
|
|
| 2017
|
Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy
2017
|
|
| 2016
|
Heparanase: From basic research to therapeutic applications in cancer and inflammation
2016
|
|
| 2016
|
Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype
2016
|
|
| 2016
|
Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: Prevention by synstatinIGF1R inhibits tumor growth
2016
|
|
| 2016
|
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.
2016
|
|
| 2016
|
Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions
2016
|
|
| 2016
|
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features
2016
|
|
| 2016
|
Recent insights into cell surface heparan sulphate proteoglycans and cancer [version 1; referees: 3 approved]
2016
|
|
| 2016
|
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
2016
|
|
| 2015
|
Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: A novel mechanism of tumor-host cross-talk
2015
|
|
| 2015
|
Heparanase is a host enzyme required for herpes simplex virus-1 release from cells
2015
|
|
| 2015
|
Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.
2015
|
|
| 2014
|
Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
2014
|
|
| 2014
|
Heparan sulfate in the nucleus and its control of cellular functions
2014
|
|
| 2013
|
Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease
2013
|
|
| 2013
|
Heparanase: Multiple functions in inflammation, diabetes and atherosclerosis
2013
|
|
| 2013
|
Involvement of heparanase in atherosclerosis and other vessel wall pathologies
2013
|
|
| 2013
|
The heparanase/syndecan-1 axis in cancer: Mechanisms and therapies
2013
|
|
| 2013
|
Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes
2013
|
|
| 2012
|
Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma
2012
|
|
| 2012
|
Targeting heparanase for cancer therapy at the tumor-matrix interface
2012
|
|
| 2012
|
Heparan sulfate chains of syndecan-1 regulate ectodomain shedding
2012
|
|
| 2011
|
Heparanase-mediated loss of nuclear syndecan-1 enhances Histone Acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype
2011
|
|
| 2011
|
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis
2011
|
|
| 2011
|
SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis
2011
|
|
| 2011
|
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity
2011
|
|
| 2010
|
Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL
2010
|
|
| 2010
|
Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis
2010
|
|
| 2010
|
Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis
2010
|
|
| 2010
|
Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis
2010
|
|
| 2009
|
Myeloma bone disease
2009
|
|
| 2009
|
Heparanase: busy at the cell surface
2009
|
|
| 2009
|
Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo
2009
|
|
| 2009
|
Heparanase regulates levels of syndecan-1 in the nucleus
2009
|
|
| 2008
|
Non-anticoagulant heparins and inhibition of cancer
2008
|
|
| 2008
|
Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma
2008
|
|
| 2008
|
Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion
2008
|
|
| 2008
|
Syndecan-1: A dynamic regulator of the myeloma microenvironment
2008
|
|
| 2007
|
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
2007
|
|
| 2007
|
Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis
2007
|
|
| 2006
|
Expression of CD138 (syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade
2006
|
|
| 2005
|
HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo
2005
|
|
| 2005
|
Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies
2005
|
|
| 2005
|
Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases
2005
|
|
| 2005
|
Identification of an invasion regulatory domain within the core protein of syndecan-1
2005
|
|
| 2005
|
Heparanase promotes the spontaneous metastasis of myeloma cells to bone
2005
|
|
| 2005
|
Dynamic remodeling of syndecan-1 structure regulates myeloma tumor growth and metastasis in vivo
2005
|
|
| 2004
|
Heparan sulfate proteoglycans and heparanase - Partners in osteolytic tumor growth and metastasis
2004
|
|
| 2004
|
Heparanase degrades syndecan-1 and perlecan heparan sulfate: Functional implications for tumor cell invasion
2004
|
|
| 2003
|
High Heparanase Activity in Multiple Myeloma Is Associated with Elevated Microvessel Density
2003
|
|
| 2003
|
The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans
2003
|
|
| 2003
|
Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface
2003
|
|
| 2003
|
Vitronectin's basic domain is a syndecan ligand which functions in trans to regulate vitronectin turnover
2003
|
|
| 2003
|
Expression of syndecan-1 is a sensitive marker for cutaneous plasmacytoma
2003
|
|
| 2002
|
Syndecan-1 in B lymphoid malignancies
2002
|
|
| 2002
|
Syndecan-1 is strongly expressed in the anagen hair follicle outer root sheath and in the dermal papilla but expression diminishes with involution of the hair follicle
2002
|
|
| 2002
|
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells
2002
|
|
| 2002
|
Soluble syndecan-1 promotes growth of myeloma tumors in vivo
2002
|
|
| 2002
|
Neoglycans, carbodiimide-modified glycosaminoglycans: A new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis
2002
|
|
| 2002
|
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
|
|
| 2002
|
6xHis promotes binding of a recombinant protein to heparan sulfate
2002
|
|
| 2002
|
Measurements of glycosaminoglycan-based cell interactions
2002
|
|
| 2002
|
The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma
2002
|
|
| 2001
|
Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions
2001
|
|
| 2001
|
Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion
2001
|
|
| 2001
|
Acantholysis and spongiosis are associated with loss of syndecan-1 expression
2001
|
|
| 2001
|
Heparan sulfate proteoglycans in invasion and metastasis
2001
|
|
| 2001
|
Regulatory roles of syndecans in cell adhesion and invasion.
2001
|
|
| 2000
|
High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity
2000
|
|
| 2000
|
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
2000
|
|
| 2000
|
The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to β1 integrin-dependent cell spreading
2000
|
|
| 2000
|
Matrix metalloproteinases in multiple myeloma
2000
|
|
| 2000
|
Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma
2000
|
|
| 1999
|
Syndecan-1 expression is diminished in acantholytic cutaneous squamous cell carcinoma
1999
|
|
| 1999
|
Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9
1999
|
|
| 1999
|
Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: A multifunctional regulator of cell behavior within the tumor microenvironment
1999
|
|
| 1999
|
Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma
1999
|
|
| 1998
|
Multiple heparan sulfate chains are required for optimal syndecan-1 function
1998
|
|
| 1998
|
Heparan sulfate proteoglycans as adhesive and anti-invasive molecules: Syndecans and glypican have distinct functions
1998
|
|
| 1998
|
Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation
1998
|
|
| 1997
|
Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma
1997
|
|
| 1996
|
Heparan sulfate proteoglycans mediate aggregation of human B lymphoid cells
1996
|
|
| 1996
|
Photoaffmity analogs for the study of glycosaminoglycan biosynthetic enzymes in human myeloma cell lines
1996
|
|
| 1995
|
Heparan sulfate-mediated cell aggregation: Syndecans-1 and -4 mediate intercellular adhesion following their transfection into human B lymphoid cells
1995
|
|
| 1995
|
Syndecans as Anti-invasive Molecules on the Surface of Tumor Cells
1995
|
|
| 1994
|
Expression of syndecan-1 inhibits cell invasion into type I collagen
1994
|
|
| 1994
|
Interactions of syndecan-1 and heparin with human collagens
1994
|
|
| 1994
|
Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior
1994
|
|
| 1994
|
Interleukin-6 regulates expression of the syndecan-1 proteoglycan on b lymphoid cells
1994
|
|
| 1993
|
Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
1993
|
|
| 1992
|
Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by the integral membrane proteoglycan, syndecan
1992
|
|
| 1992
|
Functional and molecular characterization of single, (4‐hydroxy‐3‐nitrophenyl)acetyl (NP)‐specific, IgG1+ B cells from antibody‐secreting and memory B cell pathways in the C57BL/6 immune response to NP
1992
|
|
| 1992
|
Syndecan-1, a cell-surface proteoglycan, changes in size and abundance when keratinocytes stratify
1992
|
|
| 1991
|
Expression of syndecan, a putative low affinity fibroblast growth factor receptor, in the early mouse embryo
1991
|
|
| 1991
|
Epithelial-mesenchymal interactions in uterus and vagina alter the expression of the cell surface proteoglycan, syndecan
1991
|
|
| 1990
|
Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors.
1990
|
|
| 1989
|
B lymphocytes express and lose syndecan at specific stages of differentiation.
1989
|
|
| 1988
|
Molecular polymorphism of a cell surface proteoglycan: Distinct structures on simple and stratified epithelia
1988
|
|
| 1986
|
Fibroblasts promote the formation of a continuous basal lamina during myogenesis in vitro
1986
|
|
| 1985
|
The Extracellular Matrix of Skeletal Muscle
1985
|
|
| 1984
|
Changes in the synthesis of minor cartilage collagens after growth of chick chondrocytes in 5-bromo-2′-deoxyuridine or to senescence
1984
|
|
| 1984
|
Monoclonal antibodies against chicken type IV and V collagens: Electron microscopic mapping of the epitopes after rotary shadowing
1984
|
|
| 1983
|
The use of monoclonal antibodies to fragments of chicken type IV collagen in structural and localization studies
1983
|
|
| 1983
|
Monoclonal antibodies against chicken type V collagen: Production, specificity, and use for immunocytochemical localization in embryonic cornea and other organs
1983
|
|
| 1982
|
Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagen
1982
|
|
| 1982
|
Domain and basement membrane specificity of a monoclonal antibody against chicken type IV collagen.
1982
|
|
